Cipla on 28th October informed the public about the commercialization of IgG ELISA (Enzyme-linked immunosorbent assay). It is an antibody detection tool to keep a check on Covid-19. It is launched under the name ‘ELIFast’. The technology is transferred by ICMR (Indian Council of Medical Research) to KARWA Ltd. Cipla has collaborated with Karwa for this project.
Cipla was established in 1935. Cipla’s tagline ‘Caring for Life’ depicts its mission and vision towards the medical health of people. It has been working accordingly for many decades. Cipla’s extensive circulation organization will help in guaranteeing the consistent flexible supply of kits throughout the nation. Gracefully, it will be embraced through the channels endorsed by ICMR, to guarantee impartial access. It manufactures the best quality medicines through its latest technology.
Cipla in its press release statement also said that, as a component of this shared exertion, Cipla will be liable for the advertising and appropriation of the SARS CoV-2-IgG antibody detection ELISA that will be fabricated by KARWA Ltd. ICMR has given the imperative mechanical expertise and cycle for building up the test units to the approved manufacturers.
ICMR has made sure to conduct sero – surveillance under these test kits. Sero – surveillance will help in monitoring the passing on of the coronavirus. These antibody tests check the immunity level of people to Covid-19 infection. Sero – surveillance will also assist in determining the problem of SARS-Cov-2 infection at large levels that is the community level.
ELIfast has been approved and affirmed by ICMR and the National Institute of Virology (NIV), Pune. It has a specificity of almost 99.33 percent. And it’s sensitivity is about 92 percent. The unit is easy to use with straightforward protocols with ready-to-utilize reagents and is viable with regular ELISA equipment.